Literature DB >> 23300182

Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1.

Ilaria Ambaglio1, Luca Malcovati, Elli Papaemmanuil, Coby M Laarakkers, Matteo G Della Porta, Anna Gallì, Matteo C Da Vià, Elisa Bono, Marta Ubezio, Erica Travaglino, Riccardo Albertini, Peter J Campbell, Dorine W Swinkels, Mario Cazzola.   

Abstract

Somatic mutations of the RNA splicing machinery have been recently identified in myelodysplastic syndromes. In particular, a strong association has been found between SF3B1 mutation and refractory anemia with ring sideroblasts, a condition characterized by ineffective erythropoiesis and parenchymal iron overload. We studied the relationship between SF3B1 mutation, erythroid activity and hepcidin levels in myelodysplastic syndrome patients. Erythroid activity was evaluated through the proportion of marrow erythroblasts, soluble transferrin receptor and serum growth differentiation factor 15. Significant relationships were found between SF3B1 mutation and marrow erythroblasts (P=0.001), soluble transferrin receptor (P=0.003) and serum growth differentiation factor 15 (P=0.033). Serum hepcidin varied considerably, and multivariable analysis showed that the hepcidin to ferritin ratio, a measure of adequacy of hepcidin levels relative to body iron stores, was inversely related to the SF3B1 mutation (P=0.013). These observations suggest that patients with SF3B1 mutation have inappropriately low hepcidin levels, which may explain their propensity to parenchymal iron loading.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23300182      PMCID: PMC3659929          DOI: 10.3324/haematol.2012.077446

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  27 in total

1.  Overexpression of mitochondrial ferritin causes cytosolic iron depletion and changes cellular iron homeostasis.

Authors:  Guangjun Nie; Alex D Sheftel; Sangwon F Kim; Prem Ponka
Journal:  Blood       Date:  2004-11-02       Impact factor: 22.113

2.  Myelodysplastic syndromes--coping with ineffective hematopoiesis.

Authors:  Mario Cazzola; Luca Malcovati
Journal:  N Engl J Med       Date:  2005-02-10       Impact factor: 91.245

3.  Natural history of idiopathic refractory sideroblastic anemia.

Authors:  M Cazzola; G Barosi; P G Gobbi; R Invernizzi; A Riccardi; E Ascari
Journal:  Blood       Date:  1988-02       Impact factor: 22.113

4.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

Authors:  Luca Malcovati; Matteo Giovanni Della Porta; Cristiana Pascutto; Rosangela Invernizzi; Marina Boni; Erica Travaglino; Francesco Passamonti; Luca Arcaini; Margherita Maffioli; Paolo Bernasconi; Mario Lazzarino; Mario Cazzola
Journal:  J Clin Oncol       Date:  2005-09-26       Impact factor: 44.544

5.  Hepcidin in iron overload disorders.

Authors:  George Papanikolaou; Michalis Tzilianos; John I Christakis; Dionisios Bogdanos; Konstantina Tsimirika; Julie MacFarlane; Y Paul Goldberg; Nikos Sakellaropoulos; Tomas Ganz; Elizabeta Nemeth
Journal:  Blood       Date:  2005-01-25       Impact factor: 22.113

6.  Soluble transferrin receptor as a potential determinant of iron loading in congenital anaemias due to ineffective erythropoiesis.

Authors:  M Cazzola; Y Beguin; G Bergamaschi; R Guarnone; P Cerani; S Barella; A Cao; R Galanello
Journal:  Br J Haematol       Date:  1999-09       Impact factor: 6.998

7.  Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization.

Authors:  Elizabeta Nemeth; Marie S Tuttle; Julie Powelson; Michael B Vaughn; Adriana Donovan; Diane McVey Ward; Tomas Ganz; Jerry Kaplan
Journal:  Science       Date:  2004-10-28       Impact factor: 47.728

Review 8.  The World Health Organization (WHO) classification of the myeloid neoplasms.

Authors:  James W Vardiman; Nancy Lee Harris; Richard D Brunning
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

9.  The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts.

Authors:  Maryam Nikpour; Christian Scharenberg; Anquan Liu; Simona Conte; Mohsen Karimi; Teresa Mortera-Blanco; Valentina Giai; Marta Fernandez-Mercado; Elli Papaemmanuil; Kari Högstrand; Monika Jansson; Inger Vedin; James Stephen Wainscoat; Peter Campbell; Mario Cazzola; Jacqueline Boultwood; Alf Grandien; Eva Hellström-Lindberg
Journal:  Leukemia       Date:  2012-10-16       Impact factor: 11.528

10.  Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome.

Authors:  M G Della Porta; L Malcovati; R Invernizzi; E Travaglino; C Pascutto; M Maffioli; A Gallì; S Boggi; D Pietra; L Vanelli; C Marseglia; S Levi; P Arosio; M Lazzarino; M Cazzola
Journal:  Leukemia       Date:  2006-04       Impact factor: 11.528

View more
  19 in total

Review 1.  New strategies to target iron metabolism for the treatment of beta thalassemia.

Authors:  Paraskevi Rea Oikonomidou; Carla Casu; Stefano Rivella
Journal:  Ann N Y Acad Sci       Date:  2016-02-25       Impact factor: 5.691

2.  A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome.

Authors:  Sabrina Bondu; Anne-Sophie Alary; Carine Lefèvre; Alexandre Houy; Grace Jung; Thibaud Lefebvre; David Rombaut; Ismael Boussaid; Abderrahmane Bousta; François Guillonneau; Prunelle Perrier; Samar Alsafadi; Michel Wassef; Raphaël Margueron; Alice Rousseau; Nathalie Droin; Nicolas Cagnard; Sophie Kaltenbach; Susann Winter; Anne-Sophie Kubasch; Didier Bouscary; Valeria Santini; Andrea Toma; Mathilde Hunault; Aspasia Stamatoullas; Emmanuel Gyan; Thomas Cluzeau; Uwe Platzbecker; Lionel Adès; Hervé Puy; Marc-Henri Stern; Zoubida Karim; Patrick Mayeux; Elizabeta Nemeth; Sophie Park; Tomas Ganz; Léon Kautz; Olivier Kosmider; Michaëla Fontenay
Journal:  Sci Transl Med       Date:  2019-07-10       Impact factor: 17.956

Review 3.  Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.

Authors:  Niraj Shenoy; Nishanth Vallumsetla; Eliezer Rachmilewitz; Amit Verma; Yelena Ginzburg
Journal:  Blood       Date:  2014-06-12       Impact factor: 22.113

Review 4.  Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts.

Authors:  Anna Mies; Olivier Hermine; Uwe Platzbecker
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

5.  Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions.

Authors:  Rui Cui; Robert Peter Gale; Guoqing Zhu; Zefeng Xu; Tiejun Qin; Yue Zhang; Gang Huang; Bing Li; Liwei Fang; Hongli Zhang; Lijuan Pan; Naibo Hu; Shiqiang Qu; Zhijian Xiao
Journal:  Leuk Res       Date:  2014-02-10       Impact factor: 3.156

6.  SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.

Authors:  Luca Malcovati; Mohsen Karimi; Elli Papaemmanuil; Ilaria Ambaglio; Martin Jädersten; Monika Jansson; Chiara Elena; Anna Gallì; Gunilla Walldin; Matteo G Della Porta; Klas Raaschou-Jensen; Erica Travaglino; Klaus Kallenbach; Daniela Pietra; Viktor Ljungström; Simona Conte; Emanuela Boveri; Rosangela Invernizzi; Richard Rosenquist; Peter J Campbell; Mario Cazzola; Eva Hellström Lindberg
Journal:  Blood       Date:  2015-05-08       Impact factor: 22.113

Review 7.  SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.

Authors:  Luca Malcovati; Kristen Stevenson; Elli Papaemmanuil; Donna Neuberg; Rafael Bejar; Jacqueline Boultwood; David T Bowen; Peter J Campbell; Benjamin L Ebert; Pierre Fenaux; Torsten Haferlach; Michael Heuser; Joop H Jansen; Rami S Komrokji; Jaroslaw P Maciejewski; Matthew J Walter; Michaela Fontenay; Guillermo Garcia-Manero; Timothy A Graubert; Aly Karsan; Manja Meggendorfer; Andrea Pellagatti; David A Sallman; Michael R Savona; Mikkael A Sekeres; David P Steensma; Sudhir Tauro; Felicitas Thol; Paresh Vyas; Arjan A Van de Loosdrecht; Detlef Haase; Heinz Tüchler; Peter L Greenberg; Seishi Ogawa; Eva Hellstrom-Lindberg; Mario Cazzola
Journal:  Blood       Date:  2020-07-09       Impact factor: 25.476

8.  Improved mass spectrometry assay for plasma hepcidin: detection and characterization of a novel hepcidin isoform.

Authors:  Coby M M Laarakkers; Erwin T Wiegerinck; Siem Klaver; Maria Kolodziejczyk; Hendrik Gille; Andreas M Hohlbaum; Harold Tjalsma; Dorine W Swinkels
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

Review 9.  EnvIRONmental Aspects in Myelodysplastic Syndrome.

Authors:  Verena Petzer; Igor Theurl; Günter Weiss; Dominik Wolf
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

10.  High expression of APAF-1 elevates erythroid apoptosis in iron overload myelodysplastic syndrome.

Authors:  Shucheng Gu; Youshan Zhao; Juan Guo; Feng Xu; Chengming Fei; Xi Zhang; Chao Xiao; Chunkang Chang; Xiao Li
Journal:  Tumour Biol       Date:  2013-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.